Kupando pushes forward with next‑gen cancer immunotherapy
Schönefeld-based biopharmaceutical startup Kupando is advancing a novel class of cancer immunotherapies built around a proprietary TLR 4/7 agonist. The company’s experimental platform is designed to stimulate the body’s innate immunity and induce so‑called trained immunity, potentially improving how patients respond to existing and future cancer treatments.
Harnessing innate and trained immunity
Unlike traditional approaches that focus primarily on the body’s adaptive immune system, Kupando targets the first line of defense: the innate immune response. By activating Toll‑like receptors (TLRs) 4 and 7, the company aims to trigger a controlled inflammatory reaction that can make tumors more visible to immune cells.
The concept of trained immunity refers to the ability of innate immune cells, such as monocytes and natural killer cells, to develop a memory‑like response after an initial stimulus. Kupando’s TLR 4/7 agonist is engineered to exploit this mechanism, potentially creating a longer‑lasting, more robust anti‑tumor effect without relying solely on classical T‑cell memory.
Potential to boost existing cancer treatments
Preclinical data in the broader field of immuno-oncology suggest that TLR agonists can enhance the activity of checkpoint inhibitors, cancer vaccines and other targeted therapies. By reshaping the tumor microenvironment, Kupando’s candidate could help overcome resistance that often limits the effectiveness of current drugs.
The company’s strategy is expected to focus on combination regimens, where its TLR 4/7 agonist is administered alongside established standards of care. If successful, this approach could unlock new options for patients with solid tumors that have responded poorly to existing immunotherapies.
Positioning within Europe’s biotech ecosystem
Based in the Berlin‑Brandenburg life sciences cluster, Kupando benefits from access to academic partners, clinical trial networks and specialized investors active in biopharmaceutical innovation. As the global market for cancer immunotherapy continues to grow, the company’s focus on innate and trained immunity positions it within one of the most closely watched segments of oncology research.
Further details on clinical timelines, lead indications and regulatory strategy are expected as Kupando advances its TLR 4/7 agonist toward first‑in‑human studies.